熱門資訊> 正文
波士顿科学公司完成收购Axonics
2024-11-15 22:21
- Boston Scientific (NYSE:BSX) announced the close of its acquisition of Axonics (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
- The purchase price of $71 cash per share represents an equity value of $3.7B and an enterprise value of $3.3B.
- The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter.
- On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.
- Source: Press Release
More on Boston Scientific
- Axonics' Market Growth Strengthens Boston Scientific's Future
- Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript
- Business Update
- Boston Scientific to acquire AFib ablation tech firm Cortex
- Boston Scientific ACURATE neo2 aortic valve misses primary endpoint in trial
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
